-DOCSTART- -X- O
Intravascular-thrombosis -X- _ O
and -X- _ O
extravascular-lipid-deposit -X- _ O
are -X- _ O
the -X- _ O
two -X- _ O
key -X- _ O
pathogenic -X- _ O
events -X- _ O
considered -X- _ O
to -X- _ O
interrupt -X- _ O
intraosseous -X- _ O
blood -X- _ O
supply -X- _ O
during -X- _ O
development -X- _ O
of -X- _ O
steroid-associated -X- _ B-Patient
osteonecrosis -X- _ I-Patient
( -X- _ I-Patient
ON -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
clinically -X- _ O
employed -X- _ O
agents -X- _ O
capable -X- _ O
of -X- _ O
simultaneously -X- _ O
targeting -X- _ O
these -X- _ O
two -X- _ O
key -X- _ O
pathogenic -X- _ O
events. -X- _ O
The -X- _ O
present -X- _ O
experimental -X- _ O
study -X- _ O
demonstrated -X- _ O
that -X- _ O
constitutional -X- _ B-Intervention
flavonoid -X- _ I-Intervention
glycosides -X- _ I-Intervention
derived -X- _ I-Intervention
from -X- _ I-Intervention
herb -X- _ I-Intervention
Epimedium -X- _ I-Intervention
( -X- _ I-Intervention
EF -X- _ I-Intervention
, -X- _ I-Intervention
composed -X- _ I-Intervention
of -X- _ I-Intervention
seven -X- _ I-Intervention
flavonoid -X- _ I-Intervention
compounds -X- _ I-Intervention
with -X- _ I-Intervention
common -X- _ I-Intervention
stem -X- _ I-Intervention
nuclear -X- _ I-Intervention
) -X- _ I-Intervention
exerted -X- _ B-Outcome
dose-dependent -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
both -X- _ I-Outcome
thrombosis -X- _ I-Outcome
and -X- _ I-Outcome
lipid-deposition -X- _ I-Outcome
and -X- _ I-Outcome
accordingly -X- _ I-Outcome
reducing -X- _ I-Outcome
incidence -X- _ I-Outcome
of -X- _ I-Outcome
steroid-associated -X- _ I-Outcome
ON -X- _ I-Outcome
in -X- _ I-Outcome
rabbits -X- _ I-Outcome
, -X- _ O
which -X- _ O
was -X- _ O
not -X- _ O
via -X- _ O
direct -X- _ O
action -X- _ O
by -X- _ O
themselves -X- _ O
rather -X- _ O
by -X- _ O
their -X- _ O
common -X- _ O
metabolite -X- _ O
on -X- _ O
potential -X- _ O
cellular -X- _ O
targets -X- _ O
involved -X- _ O
in -X- _ O
the -X- _ O
two -X- _ O
pathogenic -X- _ O
pathways. -X- _ O
The -X- _ O
underlying -X- _ O
mechanism -X- _ O
could -X- _ O
be -X- _ O
explained -X- _ O
by -X- _ O
counteracting -X- _ O
endothelium -X- _ O
injury -X- _ O
and -X- _ O
excessive -X- _ O
adipogenesis. -X- _ O
These -X- _ O
findings -X- _ O
encourage -X- _ O
designing -X- _ O
clinical -X- _ O
trials -X- _ O
to -X- _ O
investigate -X- _ O
potential -X- _ O
of -X- _ O
EF -X- _ B-Intervention
in -X- _ O
prevention -X- _ B-Outcome
of -X- _ O
steroid- -X- _ B-Patient
associated -X- _ I-Patient
ON -X- _ I-Patient
. -X- _ O

